Effect of thymosin-α1 on T-helper 1 cell and T-helper 2 cell cytokine synthesis in patients with hepatitis b virus e antigen-positive chronic hepatitis b

Journal of International Medical Research

Volumn 38, Issue 6, 2010, Pages 2053-2062

  Jiang, Y F ^a   Ma, Z H ^a   Zhao, P W ^a   Pan, Y ^a   Liu, Y Y ^a   Feng, J Y ^a   Niu, J Q ^a  

^a JILIN UNIVERSITY   (China)

Author keywords

Chronic hepatitis b; Cytokines; Immunomodulatory drugs

Indexed keywords

GAMMA INTERFERON; HEPATITIS E ANTIGEN; INTERLEUKIN 2; INTERLEUKIN 4; THYMOSIN ALPHA1;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG EFFICACY; FEMALE; FLOW CYTOMETRY; HEPATITIS B; HUMAN; IMMUNOTHERAPY; MALE; MONOTHERAPY; PERIPHERAL BLOOD MONONUCLEAR CELL; RANDOMIZED CONTROLLED TRIAL; TH1 CELL; TH2 CELL;

EID: 78650815174     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001003800620     Document Type: Article

References (23)

1. Mahboobi N, Agha-Hosseini F, Mahboobi N, et al: Hepatitis B virus infection in dentistry: a forgotten topic. J Viral Hepat 2010; 17: 307-316.
2. World Health Organization (WHO): Hepatitis B. WHO Fact Sheet, No. 204, revised October 2000(available at: http://www.who.int/mediacentre/factsheets/fs204/en/).
3. Li DD, Ding L, Wang J, et al: Prevalence of hepatitis B virus genotypes and their7 relationship to clinical laboratory outcomes in Tibetan and Han Chinese. J Int Med Res 2010; 38: 195-201.
4. Lavanchy D: Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11: 97-107.
5. Maddrey WC: Hepatitis B: an important public health issue. J Med Virol 2000; 61: 362-366.
6. Bertoletti A, Gehring AJ: The immune response during hepatitis B virus infection. J Gen Virol 2006; 87: 1439-1449.
7. Mosmann TR, Sad S: The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996; 17: 138-146.
8. O'Garra A: Cytokines induce the development of functionally heterogeneous T helper cell subsets. Immunity 1998; 8: 275-283.
9. Li CL, Zhang T, Saibara T, et al: Thymosin α1 accelerates restoration of T cell-mediated neutralizing antibody response in immunocompromisedhosts.Int Immunopharmacol 2002; 2: 39-46.
10. Andreone P, Cursaro C, Gramenzi A, et al: In vitro effect of thymosin-α1 and interferon-γ on Th1 and Th2 cytokine synthesis in patients with chronic hepatitis C. J Viral Hepat 2001; 8: 194-201.
11. Ferrari C, Missale G, Boni C, et al: Immunopathogenesis of hepatitis B. J Hepatol 2003; 39(suppl 1): S36-S42.
12. 1 in patients with chronic hepatitis B: a randomized, controlled trial. Hepatology 1998; 27: 1383-1387.
13. Duramad P, McMahon CW, Hubbard A, et al: Flow cytometric detection of intracellular Th1/Th2 cytokines using whole blood: validation of immunologic biomarker for use in epidemiologic studies. Cancer Epidemiol Biomarkers Prev 2004; 13: 1452-1458.
14. Papatheodoridis GV, Manolakopoulos S, Dusheiko G, et al: Therapeutic strategies in the management of patients with chronic hepatitis B virus infection. Lancet Infect Dis 2008: 8: 167-178.
15. Liaw YF: Thymalfasin (thymosin-alpha 1) therapy in patients with chronic hepatitis B. J Gastroenterol Hepatol 2004; 19 (suppl 6): S73-S75.
16. Chien RN, Liaw YF: Thymalfasin for the treatment of chronic hepatitis B. Expert Rev Anti Infect Ther 2004; 2: 9-16.
17. Jiang R, Feng X, Guo Y, et al: T helper cells in patients with chronic hepatitis B virus. infection. Chin Med J (Engl) 2002; 3: 422-424.
18. Goldstein AL, Badamchian M: Thymosins: chemistry and biological properties in health and disease. Expert Opin Biol Ther 2004; 4: 559-573.
19. 1 in combination with cytokines and chemotherapy for the treatment of cancer. Int Immunopharmacol 2003; 8: 1145-1150.
20. Sjogren MH: Thymalfasin: an immune system enhancer for the treatment of liver disease. J Gastroenterol Hepatol 2004; 19(suppl 6): S69-S72.
21. Blackburn SD, Wherry EJ: IL-10, T cell exhaustion and viral persistence. Trends Microbiol 2007; 15: 143-146.
22. Mutchnick MG, Lindsay KL, Schiff ER, et al: Thymosin-α1 treatment of chronic hepatitis B: results of a phase III multicentre, randomized, double-blind and placebo-controlled study. J Viral Hepat 1999; 6: 397-403.
23. Hyodo N, Tajimi M, Ugajin T, et al: Frequencies of interferon-gamma and interleukin-10 secreting cells in peripheral blood mononuclear cells and liver infiltrating lymphocytes in chronic hepatitis B virus infection. Hepatol Res 2003; 27: 109-116.